

Knee Osteoarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/K3DA9A978498EN.html>

Date: May 2024

Pages: 133

Price: US\$ 6,499.00 (Single User License)

ID: K3DA9A978498EN

Abstracts

The 7 major knee osteoarthritis markets reached a value of US\$ 4.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 9.1 Billion by 2034, exhibiting a growth rate (CAGR) of 6.18% during 2024-2034.

The knee osteoarthritis market has been comprehensively analyzed in IMARC's new report titled "Knee Osteoarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Knee osteoarthritis, also referred to as degenerative joint disease, is a condition characterized by the slow deterioration of connective tissues in the knee joint. As the illness progresses, the joint may become inflamed, and bony growths called bone spurs may develop in the affected area. These changes can result in pain, swelling, and difficulty performing daily functions, such as climbing stairs, walking, or bending the knee. The symptoms of the ailment can vary from person to person but commonly include stiffness, grating or popping sensations, reduced range of motion, muscle weakness, instability, etc. The diagnosis of this disorder typically involves a combination of characteristic findings, medical history, and physical examination. The healthcare provider may also perform X-rays to visualize the knee and assess the extent of joint damage. In some cases, numerous other imaging tests, such as computed tomography (CT) scans or magnetic resonance imaging (MRI), may be recommended to obtain more detailed information about the joint structures. Furthermore, an arthrocentesis is conducted to confirm the diagnosis in individuals suffering from the disease.

The increasing cases of structural abnormalities in the knee joint, such as malalignment or instability that can lead to an uneven distribution of forces across the joint surfaces, causing cartilage damage, are primarily driving the knee osteoarthritis market. In

In addition to this, the expanding geriatric population, who are prone to degenerative changes due to reduced tissue repair capacity, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical therapy, owing to its various advantages, like strengthening the muscles around the knee joint, improving flexibility, and offering pain relief to patients, is further bolstering the market growth. Apart from this, the inflating application of assistive devices, including canes, crutches, braces, etc., that help to reduce stress on the joint and provide support during movement is acting as another significant growth-inducing factor. Additionally, the emerging popularity of hyaluronic acid injections, since they improve the viscoelastic properties of the synovial fluid, thereby decreasing friction between the bones, is expected to drive the knee osteoarthritis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the knee osteoarthritis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for knee osteoarthritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the knee osteoarthritis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the knee osteoarthritis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the knee osteoarthritis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current knee osteoarthritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the knee osteoarthritis market performed so far and how will it perform in the

coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the knee osteoarthritis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the knee osteoarthritis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of knee osteoarthritis across the seven major markets?

What is the number of prevalent cases (2018-2034) of knee osteoarthritis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of knee osteoarthritis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with knee osteoarthritis across the seven major markets?

What is the size of the knee osteoarthritis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of knee osteoarthritis?

What will be the growth rate of patients across the seven major markets?

Knee Osteoarthritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for knee osteoarthritis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the knee osteoarthritis market?

What are the key regulatory events related to the knee osteoarthritis market?

What is the structure of clinical trial landscape by status related to the knee osteoarthritis market?

What is the structure of clinical trial landscape by phase related to the knee osteoarthritis market?

What is the structure of clinical trial landscape by route of administration related to the knee osteoarthritis market?

Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 KNEE OSTEOARTHRITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 KNEE OSTEOARTHRITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 KNEE OSTEOARTHRITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 KNEE OSTEOARTHRITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 KNEE OSTEOARTHRITIS - UNMET NEEDS

10 KNEE OSTEOARTHRITIS - KEY ENDPOINTS OF TREATMENT

11 KNEE OSTEOARTHRITIS - MARKETED PRODUCTS

- 11.1 List of Knee Osteoarthritis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Pennsaid (Diclofenac transdermal first generation) - Crescita Therapeutics
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Zilretta (Triamcinolone acetonide sustained release) - Flexion Therapeutics
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Supartz (Sodium hyaluronate)
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 TriVISC (Sodium hyaluronate) - OrthogenRx
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report

12 KNEE OSTEOARTHRITIS - PIPELINE DRUGS

- 12.1 List of Knee Osteoarthritis Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Lorecivivint - Biosplice Therapeutics
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 DFV 890 - Novartis
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy
 - 12.1.2.5 Regulatory Status
 - 12.1.3 LNA 043 - Novartis
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy

- 12.1.3.5 Regulatory Status
- 12.1.4 PPV-06 - Peptinov
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 GNSC 001 - Genascence Corporation
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

13. KNEE OSTEOARTHRITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. KNEE OSTEOARTHRITIS – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 KNEE OSTEOARTHRITIS - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Knee Osteoarthritis - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Knee Osteoarthritis - Market Size
 - 15.3.1.1 Market Size (2018-2023)

- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Knee Osteoarthritis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Knee Osteoarthritis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Knee Osteoarthritis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Knee Osteoarthritis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Knee Osteoarthritis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Knee Osteoarthritis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Knee Osteoarthritis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Knee Osteoarthritis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Knee Osteoarthritis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Knee Osteoarthritis - Market Size

- 15.8.1.1 Market Size (2018-2023)
- 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Knee Osteoarthritis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Knee Osteoarthritis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Knee Osteoarthritis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Knee Osteoarthritis - Access and Reimbursement Overview

16 KNEE OSTEOARTHRITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 KNEE OSTEOARTHRITIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 KNEE OSTEOARTHRITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Knee Osteoarthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/K3DA9A978498EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/K3DA9A978498EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

